{"schema_version":"secwatch.filing_event.v1","accession":"0001613103-25-000019","form_type":"8-K","ticker":"MDT","cik":"0001613103","company_name":"Medtronic plc","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.191063+00:00","generated_at":"2026-05-26T16:31:29.430735+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Medtronic Q3 FY2025 revenue $8.3B, EPS $1.39 non-GAAP beat; organic growth 4.1%","bullets":["Revenue $8.292B (+2.5% reported, +4.1% organic); GAAP EPS $1.01 (+2%), non-GAAP EPS $1.39 (+7%, above guidance).","Cardiovascular up 5% organic led by PFA (low-20s growth) and Micra (mid-20s growth); Diabetes up 10.4% organic.","Neuroscience up 5.2% organic (Neuromodulation low-double digit); Medical Surgical down 0.4% organic.","FY25 guidance reaffirmed: organic rev growth 4.75%-5%, non-GAAP EPS $5.44-$5.50.","CMS opened NCA for Renal Denervation; FDA approved additional PFA manufacturing site in Galway."],"urls":{"canonical":"https://secwatch.observer/filing/0001613103-25-000019","json":"https://secwatch.observer/filing/0001613103-25-000019.json","markdown":"https://secwatch.observer/filing/0001613103-25-000019.md","text":"https://secwatch.observer/filing/0001613103-25-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613103/000161310325000019/0001613103-25-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613103/000161310325000019/mdt-20250218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T16:31:29.430735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}